Avalo Therapeutics (AVTX) Other Accumulated Expenses (2021 - 2026)

Avalo Therapeutics (AVTX) has 6 years of Other Accumulated Expenses data on file, last reported at $327000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed 0.0% year-over-year to $327000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $327000.0, changed 0.0% from the prior year.
• Other Accumulated Expenses held at $327000.0 in Q1 2026, from $327000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $607000.0 in Q2 2023 to a low of $214000.0 in Q3 2023.
• A 5-year average of $364142.9 and a median of $327000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 115.25% in 2023, down 46.37% in 2023.
• Tracing AVTX's Other Accumulated Expenses over 5 years: stood at $508000.0 in 2022, then tumbled by 57.87% to $214000.0 in 2023, then surged by 52.8% to $327000.0 in 2024, then changed by 0.0% to $327000.0 in 2025, then changed by 0.0% to $327000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $327000.0 (Q1 2026), $327000.0 (Q4 2025), and $327000.0 (Q3 2025), per Business Quant data.